Historique du chiffre d'affaires, des bénéfices et des flux de trésorerie d'après les états financiers officiels.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
Voir les graphiques interactifs et les états complets → Modèle de valorisation (DCF) →
| Compte de résultat | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiffre d'affaires total | $165M | $113M | $15M | $1M | $0M | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $1M | $1M |
| Bénéfice brut | $157M | $113M | $15M | $1M | $0M | $1M | $1M | ($9M) | $3M | $0M | $0M | $0M | $1M | $0M |
| Marge brute % | 95.2% | 99.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -20858.1% | 6717.0% | 100.0% | 100.0% | 100.0% | 100.0% | 57.8% |
| Résultat opérationnel (EBIT) | ($253M) | ($256M) | ($344M) | ($362M) | ($351M) | ($330M) | ($221M) | ($67M) | ($98M) | ($99M) | ($124M) | ($239M) | ($6M) | ($2M) |
| Marge opérationnelle % | -153.3% | -226.0% | -2334.2% | -58239.5% | -146374.2% | -35361.9% | -36509.1% | -155597.7% | -209338.3% | -220266.7% | -282954.6% | -101218.6% | -969.1% | -378.2% |
| Résultat net | ($992M) | ($351M) | ($414M) | ($583M) | ($417M) | ($347M) | ($222M) | ($66M) | ($96M) | ($96M) | ($121M) | ($237M) | ($6M) | ($2M) |
| Marge nette % | -601.2% | -310.2% | -2804.8% | -93761.4% | -173569.6% | -37129.6% | -36669.6% | -152997.7% | -204736.2% | -214273.3% | -274565.9% | -100371.2% | -969.3% | -341.2% |
| EBITDA | ($889M) | ($224M) | ($264M) | ($479M) | ($352M) | ($321M) | ($204M) | ($57M) | ($87M) | ($91M) | ($118M) | ($236M) | ($6M) | ($2M) |
| Bénéfice par action (EPS) | $-0.97 | $-0.38 | $-0.59 | $-1.15 | $-1.04 | $-0.89 | $-0.58 | $-0.17 | $-0.30 | $-0.30 | $-0.37 | $-0.83 | $-0.02 | $-0.01 |
| Actions en circulation (M) | 1,050M | 920M | 700M | 509M | 400M | 389M | 383M | 383M | 325M | 322M | 328M | 286M | 316M | 316M |
Source : rapports publics de la société (SEC). Vérifiez sur SEC EDGAR avant de vous fier à tout chiffre.
Bilans, flux de trésorerie, données trimestrielles et ratios complets dans le visualiseur interactif de IBRX. /companies/us/IBRX
Les informations de ce site sont fournies à des fins éducatives et informatives uniquement ; elles ne constituent pas un conseil en investissement. Aucun objectif de cours ni recommandation n'est publié.
About TickerBase · Data methodology & sources · Privacy · Terms